Dalmelitinib is a selective, orally active c-Met kinase inhibitor (IC50: 2.9 nM) that binds the ATP-binding region of c-Met. Dalmelitinib induces phosphorylation of MET and partially or completely inhibits phosphorylation of AKT and ERK. dalmelitinib exhibits a potent inhibitory effect on the proliferation of cancer cells (c-Met oncogene amplification) and can be used in cancer research (e.g. non-small cell lung cancer).
Molecular Weight:
461.47
CAS Number:
[1637658-98-0]
Formula:
C22H16FN7O2S
Target:
Others|||c-Met/HGFR
T62911
* VAT and and shipping costs not included. Errors and price changes excepted
